Loading
A phase 1/2 trial of CD19-targeted chimeric antigen receptor T-cell in diffuse large B-cell lymphoma and follicular lymphoma, run by Pell Bio-Med Technology Co., Ltd., now recruiting.
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma is a phase 1/2 interventional study registered as NCT05326243 by Pell Bio-Med Technology Co., Ltd., with 49 participants planned, started 2022-05-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: CD19-targeted chimeric antigen receptor T-cell.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD19, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/